Will our cardiomyopathy patients accept gene therapy?

Novel techniques such as gene therapy are becoming available in an attempt to cure inherited diseases. Before these new therapies can be offered to patients, we need to be aware of potential reservations or objections, not only from patients and their surroundings but also from the public. In additi...

Descripción completa

Detalles Bibliográficos
Autores principales: Doevendans, P. A., Kupatt, C., Giacca, M., Glijnis, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2022
Materias:
Point of View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270505/
https://www.ncbi.nlm.nih.gov/pubmed/35235143
http://dx.doi.org/10.1007/s12471-022-01665-z
_version_ 1784744483142762496
author Doevendans, P. A.
Kupatt, C.
Giacca, M.
Glijnis, P.
author_facet Doevendans, P. A.
Kupatt, C.
Giacca, M.
Glijnis, P.
author_sort Doevendans, P. A.
collection PubMed
description Novel techniques such as gene therapy are becoming available in an attempt to cure inherited diseases. Before these new therapies can be offered to patients, we need to be aware of potential reservations or objections, not only from patients and their surroundings but also from the public. In addition, legal issues and costs need attention before curative gene therapy can be applied in the clinic. As this therapeutic approach is closer to becoming a reality, now is the right time to start the debate.
format Online
Article
Text
id pubmed-9270505
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bohn Stafleu van Loghum
record_format MEDLINE/PubMed
spelling pubmed-92705052022-07-10 Will our cardiomyopathy patients accept gene therapy? Doevendans, P. A. Kupatt, C. Giacca, M. Glijnis, P. Neth Heart J Point of View Novel techniques such as gene therapy are becoming available in an attempt to cure inherited diseases. Before these new therapies can be offered to patients, we need to be aware of potential reservations or objections, not only from patients and their surroundings but also from the public. In addition, legal issues and costs need attention before curative gene therapy can be applied in the clinic. As this therapeutic approach is closer to becoming a reality, now is the right time to start the debate. Bohn Stafleu van Loghum 2022-03-02 2022-07 /pmc/articles/PMC9270505/ /pubmed/35235143 http://dx.doi.org/10.1007/s12471-022-01665-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Point of View
Doevendans, P. A.
Kupatt, C.
Giacca, M.
Glijnis, P.
Will our cardiomyopathy patients accept gene therapy?
title Will our cardiomyopathy patients accept gene therapy?
title_full Will our cardiomyopathy patients accept gene therapy?
title_fullStr Will our cardiomyopathy patients accept gene therapy?
title_full_unstemmed Will our cardiomyopathy patients accept gene therapy?
title_short Will our cardiomyopathy patients accept gene therapy?
title_sort will our cardiomyopathy patients accept gene therapy?
topic Point of View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270505/
https://www.ncbi.nlm.nih.gov/pubmed/35235143
http://dx.doi.org/10.1007/s12471-022-01665-z
work_keys_str_mv AT doevendanspa willourcardiomyopathypatientsacceptgenetherapy
AT kupattc willourcardiomyopathypatientsacceptgenetherapy
AT giaccam willourcardiomyopathypatientsacceptgenetherapy
AT glijnisp willourcardiomyopathypatientsacceptgenetherapy

Ejemplares similares